Orphan designation: bexmarilimab Treatment of myelodysplastic syndromes, 25/03/2025 Positive | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 4 April 2025 - 12:43

Orphan designation: bexmarilimab Treatment of myelodysplastic syndromes, 25/03/2025 Positive

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3044

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters